Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,206Revenue $M2.6Net Margin (%)0Z-Score50.4
Enterprise Value $M1,032EPS $-0.7Operating Margin %0F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book7.410-y EBITDA Growth Rate %-33.0Quick Ratio11.9Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-3.2Current Ratio11.9Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-47.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-50.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M118ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 10.2666%Sold Out0
ACHNJean-Marie Eveillard 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 10.2672%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 10.2628%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 10.267%Reduce -50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 10.2640%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 10.2638%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-34.13 view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-29.73 view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.23.33 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-5.64 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-6.64 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$20356.3-99.95 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$12.45-15.34 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-02Sell835,293$11.63-9.37 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-27Sell2,711,352$11.33-6.97 view
Truitt JosephEVP, Chief Commercial Officer 2014-08-25Sell25,000$10.82-2.59 view

Press Releases about ACHN :

    Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
    Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    comment on ACHN Mar 15 2013 
    comment on ACHN Mar 09 2013 
    Achillion Will Surge If New Drug Is Successful Apr 22 2012 
    Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 24 2012 
    Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 


    More From Other Websites
    Most active Nasdaq-traded stocks Apr 14 2015
    Nasdaq stocks posting largest percentage decreases Apr 14 2015
    Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL) Apr 08 2015
    Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL) Apr 08 2015
    The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals... Mar 30 2015
    Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the... Mar 30 2015
    Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog Mar 27 2015
    Steadymed Ltd (STDY), Achillion Pharmaceuticals, Inc. (ACHN), & Nevro Corp (NVRO): James Flynn’s... Mar 27 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 24 2015
    Lightning Round: Too much competition in this Mar 20 2015
    Cramer Remix: Cha-ching! Time to cash in Mar 20 2015
    ACHILLION PHARMACEUTICALS INC Financials Mar 13 2015
    Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog Mar 11 2015
    10-K for Achillion Pharmaceuticals, Inc. Mar 07 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 05 2015
    Achillion Pharmaceuticals (ACHN) Stock Tanking Today on Heavy Volume Mar 05 2015
    Achillion Reports 2014 Fourth Quarter and Year-End Financial Results Mar 05 2015
    Should You Sell Achillion Pharmaceuticals (ACHN) Before Earnings? - Tale of the Tape Mar 05 2015
    Achillion reports 4Q loss Mar 05 2015
    Achillion Reports 2014 Fourth Quarter and Year-End Financial Results Mar 05 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK